CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for E-QURE Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

E-QURE Corp
20 WEST 64TH STREET, SUITE 39G
Phone: (972) 544-27777p:972 544-27777 NEW YORK, NY  10023  United States Fax: (302) 645-1280f:302 645-1280
This company is no longer actively traded on any major stock exchange.
Business Summary
E-Qure Corp. is a medical device company that is focused on commercializing its Bioelectrical Signal Therapy Device (BST Device). The BST Device is a non-invasive, painless and easy to use electrotherapy. The Company's non-invasive BST electrical transmission Device mimics the naturally occurring pulses of healing wounds (normal wounds) and creates an electric induction field around the hard-to-heal wound, which accelerates the healing rate. The BST Device stimulates renewed blood flow and oxygen to induce local cell regeneration and therefore promote wound healing. The BST Device is designed to treat chronic wounds, primarily Stage III and Stage IV ulcers. The BST Device is used for the treatment of chronic wounds that include diabetic foot ulcers, vascular (venous or arterial), leg ulcers and pressure (decubitus) ulcers. The BST Device can accelerate healing with rapid wound closure from 45 to 60 days.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202112/31/2020YesYes---

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board RonWeissberg 63 12/27/2013 12/27/2013
Chief Executive Officer, Director OhadGoren 48 12/31/2018 6/1/2014
Chief Financial Officer GalPeleg 41 8/1/2014 8/1/2014
Chief Technology Officer, Director Itsik BenYesha 67 12/31/2018 6/1/2014
Independent Director MichaelSessler 60 8/1/2014 8/1/2014

Business Names
Business Name
Centriforce Technology Corp.
Esqure Advanced Medical Devices Ltd.

General Information
Outstanding Shares: 34,546,060 (As of 1/13/2022)
Stock Exchange: OTC
Federal Tax Id: 471691054
Fax Number: (302) 645-1280


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 10, 2024